Presbyopia in South Africa: What 2026’s New Eye Drops Mean for the Millions Still Reading at Arm’s Length

Menus held further away. Phone screens pushed out at arm’s length. A sudden need for better light over the kitchen table to read the fine print on a packet. If you’re over 40, none of this needs explaining, it’s probably already happening to you. Presbyopia, the gradual loss of the eye’s ability to focus up close, is the one eye condition virtually guaranteed to affect everyone who lives long enough to reach midlife. In 2026, it’s also a condition going through the most significant treatment shift in decades, with a fourth prescription eye drop now approved internationally in January alone. Here’s what’s actually new, and what it means for South Africans, where the gap between “needs reading correction” and “has it” is wider than most people realise.

What Presbyopia Actually Is

Inside the eye, the lens sits just behind the iris and changes shape to focus light from different distances, a process called accommodation. In childhood and early adulthood, that lens is flexible enough to snap quickly from a distant view to a book held close. From around the mid-30s onward, the lens gradually stiffens and the surrounding muscle loses some of its pulling power, so near focusing becomes slower and, eventually, impossible without help. By the early-to-mid 40s, most people notice it clearly: words blur at normal reading distance, eye strain builds during close work, and headaches appear after an evening spent on a phone or a book. Unlike most of the conditions we’ve written about this year, presbyopia isn’t a disease to be screened for and hopefully ruled out. It’s a near-universal, entirely normal part of ageing eyes, which is exactly why it’s so easy to under-treat rather than under-detect.

Why the Local Picture Is More Serious Than “Just Get Reading Glasses”

Globally, an estimated 1.8 billion people have presbyopia, and of those, around 826 million are living with uncorrected or inadequately corrected near vision, meaning the reading glasses or lenses they need simply aren’t in their hands. In sub-Saharan Africa, unaddressed presbyopia is the second-largest cause of near vision impairment after cataracts, responsible for an estimated 48.5% of moderate-to-severe cases, and prevalence studies from Nigeria have found rates as high as 59.7% to 63.4% in the age groups studied.

South African data tells a similarly uneven story. A KwaZulu-Natal study found presbyopia prevalence as high as 77.0% among the population examined, while a review of 29 public hospitals in Limpopo Province found a 28.1% prevalence of moderate-to-severe vision impairment, driven primarily by uncorrected refractive errors, presbyopia included. A 2025 study published in African Vision and Eye Health, analysing near vision correction needs at a rural Limpopo optometry clinic, links this directly to socioeconomic factors: poverty, unemployment, and a lack of medical aid cover that leaves many patients dependent on public facilities where optical services are often undersupplied relative to demand. None of this is about awareness of symptoms, everyone eventually notices blurred near vision. It’s about whether the straightforward, inexpensive correction that fixes it is actually reaching people, and in much of Limpopo, the data suggests it often isn’t.

What’s New in Presbyopia Care in 2026

For decades, the only answers to presbyopia were reading glasses, multifocal lenses, or contact lenses. That’s changed dramatically over the past five years, and 2026 has already added a fourth option to a genuinely new category of treatment: prescription eye drops that temporarily sharpen near vision.

Vuity (pilocarpine 1.25%). The first of this new class, approved in the United States in October 2021. It works by constricting the pupil to create a “pinhole effect” that extends depth of focus, sharpening near vision within about 15 minutes and lasting roughly 6 to 10 hours per dose.

Qlosi (pilocarpine 0.4%). A lower-dose, preservative-free alternative approved in October 2023, designed to act more selectively on the pupil with less effect on the eye’s own focusing muscle, with benefits lasting up to 8 hours.

Vizz (aceclidine 1.44%). Approved in the United States in July 2025, this was the first aceclidine-based presbyopia drop, using a two-drop application technique and offering one of the longest durations in the class, up to 10 hours from a single dose.

Yuvezzi (carbachol 2.75% / brimonidine tartrate 0.1%). The newest entrant, approved in the United States on 28 January 2026. This combination drop pairs carbachol, which constricts the pupil, with brimonidine, which helps sustain that constriction, and its Phase 3 BRIO trials showed statistically significant three-line-or-greater improvements in near vision lasting up to 8 hours, with no treatment-related serious adverse events recorded across more than 72,000 treatment days.

It’s worth being direct about what this means locally: these are approvals from the US regulator, and as of now, none of the four has completed registration with SAHPRA for sale in South African pharmacies. They matter here anyway, because they represent where global presbyopia management is heading, and because an increasing number of patients arrive having read about them online and want an informed opinion rather than a blank look. For the time being, the dependable, available options for South African patients remain well-fitted reading glasses, multifocal and progressive spectacle lenses, and multifocal contact lenses, along with extended depth-of-focus or multifocal lens implants for patients already having cataract surgery. Professional bodies internationally, including a 2024 global standard-of-care initiative from the World Council of Optometry, have also pushed presbyopia management toward a more structured, proactive model rather than a single pair of off-the-shelf reading glasses grabbed from a pharmacy shelf, which tends to under-correct one eye or over-correct the other far more often than patients realise.

Who This Affects, and Why “Just Get Readers” Isn’t Always Right

Presbyopia doesn’t skip anyone, previously perfect vision offers no protection, and it progresses gradually through your 40s and 50s before generally stabilising. The warning signs are familiar to almost everyone past 40: holding reading material further away than feels natural, needing noticeably brighter light to read comfortably, eye strain or headaches after sustained close work, or blur that clears the moment you look up at something further away. What’s less well understood is that generic, one-size-fits-all reading glasses, while better than nothing, frequently mismatch a person’s actual prescription, correct both eyes identically when they rarely need identical correction, and ignore any underlying astigmatism or distance prescription entirely. For the many South African patients the research shows are relying on whatever correction they can access rather than what’s properly measured for their eyes, that gap is exactly where an optometrist adds real, measurable value.

What This Means for Your Next Eye Examination

At Jason Stander Optometrists, presbyopia assessment is a standard part of every comprehensive eye examination for patients from their late 30s onward, not something raised only once someone complains of blurry print. That means properly measuring the near correction each eye actually needs, discussing whether spectacles, multifocal contact lenses, or another option suits your lifestyle best, and keeping an honest eye on which of the newer pharmacological treatments eventually reach South African shelves.

Book a comprehensive eye examination with Jason Stander Optometrists at Shop 7, Cycad Centre, Bendor, Polokwane. If you’ve started holding your phone a little further away or reaching for better light to read, there’s no need to make do with whatever reading glasses are closest to hand, a proper near vision assessment takes one visit to get right.

Jason Stander (BOptom RAU, FOA SA, CAS SA) has practised optometry in Polokwane for over a decade, combining clinical precision with a genuine flair for helping patients see and feel their best.